Resistant Mycoplasma pneumoniae in children
Abstract
Question: A 5-year-old child was seen in our clinic with a clinical presentation consistent with community-acquired pneumonia. She was prescribed a course of amoxicillin and azithromycin, but remained febrile and returned to the clinic 3 days later. The family just returned from a trip to Japan. What is the current available evidence for treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia?
Answer: Macrolide-resistant M pneumoniae (MRMP) rates are increasing worldwide, with especially high prevalence in China, Japan, and Taiwan. Most evidence in children supports the use of tetracyclines for MRMP with more limited evidence supporting fluoroquinolones for this indication. Children with M pneumoniae pneumonia and a history of recent travel to countries with high rates of resistance or who do not improve within 48 to 72 hours of macrolide treatment should be treated with 2 mg/kg of doxycycline orally twice daily (maximum 100 mg per dose).
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.